StartsideME • NASDAQ
add
23andMe Holding Co.
3,11 $
Etterbørs:(3,54 %)+0,11
3,22 $
Stengt: 22. nov., 18:26:25 GMT-5 · USD · NASDAQ · Ansvarsfraskrivelse
Forrige sluttkurs
3,23 $
Dagsintervall
2,99 $ - 3,21 $
Årsintervall
2,66 $ - 20,20 $
Markedsverdi
74,94 mill. USD
Gjennomsnittlig volum
404,88k
P/E-tall
-
Utbytte
-
Hovedbørs
NASDAQ
I nyhetene
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
(USD) | sep. 2024info | Endring år til år |
---|---|---|
Omsetning | 44,07 mill. | −11,86 % |
Driftskostnader | 81,33 mill. | −17,18 % |
Nettoomsetning | −59,10 mill. | 21,48 % |
Netto resultatmargin | −134,11 | 10,91 % |
Fortjeneste per aksje | — | — |
EBITDA | −54,96 mill. | 21,06 % |
Faktisk avgiftssats | 0,07 % | — |
Balanseregnskap
Totale aktiva
Totale passiva
(USD) | sep. 2024info | Endring år til år |
---|---|---|
Kontant / kortsiktige inv. | 126,60 mill. | −50,62 % |
Totale aktiva | 318,94 mill. | −60,19 % |
Totale passiva | 217,01 mill. | 23,31 % |
Total egenkapital | 101,93 mill. | — |
Utestående aksjer | 26,12 mill. | — |
P/B-forhold | 0,82 | — |
Avkastning på aktiva | −42,89 % | — |
Avkastning på kapital | −75,30 % | — |
Kontantstrøm
Netto kontantstrøm
(USD) | sep. 2024info | Endring år til år |
---|---|---|
Nettoomsetning | −59,10 mill. | 21,48 % |
Kontantstrøm fra drift | −40,93 mill. | 28,34 % |
Kontanter fra investering | −2,70 mill. | 2,63 % |
Kontanter fra finansiering | 260,00k | −83,68 % |
Netto kontantstrøm | −43,37 mill. | 25,18 % |
Fri kontantstrøm | −12,82 mill. | 59,90 % |
Om
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping, to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.
Founded in 2006, 23andMe soon became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use. Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.
The company had a previously fraught relationship with the United States Food and Drug Administration due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval. 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014, and in the UK since December 2014. Wikipedia
Administrerende direktør
Grunnlagt
apr. 2006
Hovedkvarter
Nettsted
Ansatte
571